Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001067781 | SCV001232861 | likely benign | not provided | 2024-12-02 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV001195388 | SCV001365737 | uncertain significance | not specified | 2019-08-27 | criteria provided, single submitter | clinical testing | The p.Ser183Leu variant in MYO7A has not been previously reported in individuals with Usher syndrome, but has been identified in 0.1% (49/35372) of Latino chromosomes by gnomAD (http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PP3, BS1_Supporting. |
Gene |
RCV001067781 | SCV001871190 | uncertain significance | not provided | 2024-09-16 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 34515852) |
Prevention |
RCV004536131 | SCV004114789 | uncertain significance | MYO7A-related disorder | 2022-11-02 | criteria provided, single submitter | clinical testing | The MYO7A c.548C>T variant is predicted to result in the amino acid substitution p.Ser183Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.14% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/11-76867783-C-T). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Natera, |
RCV001275893 | SCV001461543 | uncertain significance | Usher syndrome type 1B | 2020-09-16 | no assertion criteria provided | clinical testing |